City of Hope’s Cutting-Edge Cancer Research to Dominate ASCO 2026, Setting New Standards in Immunotherapy and Precision Medicine
As the oncology world prepares to convene in Chicago for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, City of Hope emerges as a commanding presence with 49 groundbreaking abstracts that will advance the scientific dialogue surrounding cancer treatment and research. This comprehensive body of work encompasses the latest developments in immunotherapy, biomarker discovery, and innovative therapeutic combinations that promise to reshape standards for both hematologic malignancies and solid tumors.
City of Hope, known for its robust integration of advanced scientific discovery and clinical application, has demonstrated a compelling commitment to pushing the frontiers of cancer care. At this year’s ASCO meeting, their contributions signal a pivotal evolution towards treatment paradigms that emphasize precision medicine — tailoring therapy based on individual genetic, molecular, and immunological profiles. The center’s physician-scientists are not only presenting data but will also lead critical sessions, panel discussions, and educational symposia, underscoring their leadership within the global oncology community.
Among the highlights is the phase 3 SUNMO trial, which investigates the efficacy and safety of mosunetuzumab combined with polatuzumab vedotin (Mosun-Pola) compared with the established rituximab, gemcitabine, and oxaliplatin regimen (R-GemOx) in relapsed/refractory large B-cell lymphoma (LBCL). The updated data dissect outcomes in second-line versus later-line treatment settings, providing nuanced insights that could influence clinical decision-making in lymphoma subtypes resistant to previous therapies. These findings stress the importance of bispecific antibodies and antibody-drug conjugates in overcoming therapeutic resistance mechanisms.
Another frontier explored by City of Hope’s research includes a first-in-human phase 1 study of ABBV-969, a novel therapeutic targeting metastatic castration-resistant prostate cancer (mCRPC). The investigation covers safety, pharmacokinetics, and preliminary efficacy metrics, aiming to carve a new pathway in prostate cancer management by exploiting molecular vulnerabilities unique to advanced disease phenotypes.
Intricately linking microbiome science with immuno-oncology, a standout study evaluates microbial dysbiosis as a biomarker predicting response to CBM588 when used alongside immune checkpoint blockade (ICB) therapies for metastatic renal cell carcinoma (mRCC). This innovative research adds a layer of complexity to personalizing cancer immunotherapies, suggesting that microbial ecosystem modulation could potentiate therapeutic efficacy and patient outcomes.
City of Hope’s commitment to combining molecularly targeted agents is further embodied in the randomized phase II SWOG S2001 trial, comparing the use of olaparib plus pembrolizumab with olaparib monotherapy as maintenance strategies in metastatic pancreatic cancer patients harboring germline BRCA1 or BRCA2 mutations. This trial hones in on synergistic immuno-genomic approaches to combat notoriously aggressive and refractory pancreatic tumors.
In parallel, dose-finding results emerging from a phase 1/2 study of tegavivint, a downstream Wnt/β-catenin pathway inhibitor, in advanced hepatocellular carcinoma (aHCC) highlight efforts to disrupt key oncogenic signaling nodes. Given the canonical Wnt pathway’s critical role in tumor proliferation and survival, these findings present promising avenues for targeting hepatobiliary malignancies often resistant to current interventions.
City of Hope does not merely contribute abstracts; it drives plenary discussions shaping contemporary oncology thought. For instance, the phase 3 LIBERTTO-432 trial evaluation of adjuvant selpercatinib in stage IB-IIIA RET fusion-positive non-small cell lung cancer (NSCLC) demonstrates improved event-free survival, emphasizing precision oncology’s expanding role even in early-stage disease.
Leading voices from City of Hope, such as Dr. Kristin Higgins, Chair and Moderator of a lung cancer case-based panel, dissect complex treatment pathways in ALK-positive NSCLC, navigating therapeutic decisions from early to advanced stages. Concurrently, hematologic malignancies expert Dr. Amrita Krishnan moderates critical discussion around treatment depth and risk in multiple myeloma, reflecting the center’s multifaceted expertise.
Immunotherapy continues to be a central theme with Dr. Tycel Phillips summarizing strategies to tailor immune interventions for relapsed lymphoma, reflecting the growing implications of bispecific antibodies, checkpoint inhibitors, and cellular therapies in refractory settings.
Prostate cancer management is also refined under City of Hope’s stewardship, as Dr. Tanya Dorff presents a comprehensive overview of personalized treatments spanning the entire disease spectrum, underscoring innovations that integrate genomic profiling, novel agents, and therapeutic sequencing.
The clinical exposition is complemented by educational sessions, such as those led by Dr. Charles Nguyen, who unpacks frontline therapeutic strategies in papillary renal cell carcinoma, a subtype demanding precise molecularly guided treatments.
City of Hope’s continued influence is mirrored by institutional honors, including Dr. John Carpten receiving the prestigious 2026 Allen Lichter Visionary Leader Award from ASCO. His groundbreaking work in cancer genomics and precision medicine has shaped strategic national research agendas and exemplifies the visionary leadership driving City of Hope’s mission.
The recognition extends to newly inducted Fellows of the American Society of Clinical Oncology (FASCO) from City of Hope, acknowledging sustained leadership and contributions in oncology care, research, and education. Drs. Arjun Gupta, Tanya Dorff, and Walter Stadler represent the breadth of expertise and dedication within this national oncology powerhouse.
City of Hope’s integrated approach, converging innovative research, clinical trials, and educational leadership, reinforces its position at the vanguard of oncology. Their expansive portfolio presented at ASCO 2026 not only charts the current science but shapes future paradigms designed to deliver therapies that are more personalized, tolerable, and efficacious.
The developments set forth by City of Hope’s research teams epitomize the crossroads of technological progress and medical ingenuity, heralding an era where cancer care transcends traditional boundaries and embodies tailored precision that elevates patient survival and quality of life.
As ASCO 2026 unfolds, City of Hope’s contributions are poised to inspire novel treatment algorithms, inform policy decisions, and galvanize the oncology community towards breakthroughs that reverberate across the spectrum of cancer biology and therapeutics.
Subject of Research: Cancer immunotherapy, precision medicine, novel therapeutic strategies, hematologic malignancies, solid tumors.
Article Title: City of Hope Scientists Unveil Pioneering Advances in Cancer Treatment at ASCO 2026.
News Publication Date: 2026.
Web References: https://www.cityofhope.org/asco-2026
Keywords: Immunotherapy, Precision Medicine, Metastatic Cancer, Hematologic Malignancies, Bispecific Antibodies, Cancer Genomics, Clinical Trials, Biomarkers, Wnt/β-catenin Inhibition, Immune Checkpoint Blockade, Prostate Cancer, Pancreatic Cancer.
